Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BMRN - BioMarin Pharmaceutical Inc.
Market Cap 16.59B P/E 238.89 EPS this Y 135.60% Ern Qtrly Grth 91.20%
Income 256.59M Forward P/E 35.22 EPS next Y 51.20% 50D Avg Chg -1.00%
Sales 2.59B PEG 0.80 EPS past 5Y 5.50% 200D Avg Chg -8.00%
Dividend N/A Price/Book 3.48 EPS next 5Y 43.00% 52W High Chg -25.00%
Recommedations 2.00 Quick Ratio 1.80 Shares Outstanding 190.38M 52W Low Chg 10.00%
Insider Own 0.87% ROA 2.23% Shares Float 188.74M Beta 0.32
Inst Own 99.59% ROE 5.10% Shares Shorted/Prior 6.01M/6.65M Price 88.39
Gross Margin 50.13% Profit Margin 9.91% Avg. Volume 1,238,693 Target Price 103.45
Oper. Margin 16.92% Earnings Date Oct 30 Volume 1,105,230 Change -0.69%
Healthcare | Biotechnology | United States
About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc. News
11/20/24 Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
11/19/24 BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now
11/16/24 BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
11/12/24 Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options
11/07/24 Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)
11/06/24 BioMarin to Participate in Three Upcoming Investor Conferences
11/05/24 Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
11/04/24 Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
11/04/24 BioMarin (BMRN) Upgraded to Buy: Here's Why
11/04/24 BMRN vs. INCY: Which Stock Is the Better Value Option?
11/04/24 Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
11/01/24 Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
10/31/24 BioMarin price target raised to $106 from $104 at UBS
10/31/24 BioMarin Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations
10/30/24 Q3 2024 BioMarin Pharmaceutical Inc Earnings Call
10/30/24 BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
10/30/24 Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
10/29/24 BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10/29/24 BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates
10/29/24 BioMarin: Q3 Earnings Snapshot
BMRN Chatroom

User Image scienceleads Posted - 21 hours ago

$BMRN expected annual revenue growth and entrenched in gene therapy with worldwide intellectual property rights and ready to expand its markets. Just saying!

User Image Trejenzky Posted - 2 days ago

$BMRN The average price target for BioMarin Pharmaceutical is $98.52. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $139.00 ,the lowest forecast was $65.00. 🚀

User Image cubie Posted - 2 days ago

@jenbunn @judgeyoung2 @Alvi722 @lowfloatscambuster @EBE_Day @Ollip @ribbey @TraderRapp @tonyctl @lukenight $biib $BMRN 52 week lows today, $UTHR $tmo $regn more pharma and bio related stonks that pullbacked lot recently

User Image Daninv8791 Posted - 2 days ago

$BMRN solid company, added some shares

User Image CDMO Posted - 2 days ago

$BMRN what kind of shit is this

User Image HankofTroy Posted - 2 days ago

$BMRN this one is tough to watch, even harder to add but I have confidence it will turn away from this 10yr low... hhmmmm

User Image _Contrairian_ Posted - 2 days ago

$BMRN time to buy now

User Image Here4theartcle Posted - 2 days ago

$BMRN whatever Eliott Advisors is advising has been terrible, thus far. Since there arrival, this stock has gone straight to the dump. This a 5 year low? Sell this POS already to

User Image scienceleads Posted - 5 days ago

$BMRN when it turns, it will really turn imho

User Image mcdicedtea Posted - 5 days ago

$BMRN wolfe (who are they) put out an outperform and 95 target. Great day to do it.

User Image daytraderShane Posted - 1 week ago

$BMRN is this due for a bounce?

User Image CDMO Posted - 1 week ago

$BMRN 66,66

User Image swingingtech Posted - 1 week ago

$CAR, $BMRN, $GOOG https://wallstreetwaves.com/highlighting-wednesdays-significant-options-activity-car-bmrn-goog/

User Image OptionRunners Posted - 1 week ago

$BMRN - Buyer of the April 17th 2025 $70/$90 call spreads 2,000 times for $4.30

User Image LauriceGeel Posted - 1 week ago

📈 Stock Performance for $BMRN over the Last Month: Opening Price: $70.40 Closing Price: $66.13 Highest Price: $70.98 Lowest Price: $65.35 Percentage Change: -6.07% 📊 Financial Summary: Revenue: 2,419,226,000 Net Income: 167,645,000 Total Assets: 6,841,603,000 Total Liabilities: 1,890,054,000 Operating Cash Flow: N/A Note: For a secret strategy and more detailed information, please visit the link in my bio. Thank you!

User Image mcdicedtea Posted - 1 week ago

$BMRN take the phones away from the kiddies. 5 shares in premarket. Sec needs rules for trading and accts so high school kids can't trade.

User Image scienceleads Posted - 2 weeks ago

$BMRN bullish down here & if the election means anything to M&A opportunities, this company should be at the front of the line. IMHO no guarantee and always risky-I’ve added yesterday. Not an expert and continually disappointed.

User Image smartkarma Posted - 2 weeks ago

$BMRN | BioMarin Pharmaceutical Inc.: Enhancement of Enzyme Replacement Therapy (ERT) Portfolio "BioMarin Pharmaceutical Inc. delivered a robust performance in the third quarter of 2024, highlighting significant year-on-year growth across its..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/biomarin-pharmaceutical-inc-enhancement-of-enzyme-replacement-therapy-ert-portfolio

User Image WhisperNumber Posted - 2 weeks ago

$EXAS #earnings after close, the expectation from the WhisperNumber community is $0.17, 38c ahead of analyst estimates. Earnings came in $0.29 ahead of the whisper last quarter. 57% beat rate. Implied move +/-12.7%. https://www.whispernumber.com/wr_alerts.jsp #options #trading $PCVX $BMRN $NBIX

User Image HankofTroy Posted - 2 weeks ago

$BMRN please show me 70 again, GTFO, your fired !

User Image IN0V8 Posted - 2 weeks ago

$BMRN Wedbush assumes coverage with outperform rating Wedbush assumes coverage with target price $94

User Image Stoxpo Posted - 2 weeks ago

BioMarin Pharmaceuticals’ New Strategy Promises Strong Upside, Led by Voxzogo and Roctavian 📢👇 Wedbush Securities’ “Outperform” rating underscores confidence in BioMarin’s vision https://stoxpo.com/index.php/2024/11/05/biomarin-pharmaceuticals-new-strategy-promises-strong-upside-led-by-voxzogo-and-roctavian/ $BMRN $QQQ

User Image doctordinero Posted - 2 weeks ago

$BMRN New business unit. $IBB https://careers.biomarin.com/job/san-rafael/head-of-marketing-skeletal-conditions-business-unit/5804/72078041136

User Image CallingStorms Posted - 10/31/24

$BMRN definitely taking this one on the chin.

User Image Benzinga Posted - 10/30/24

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth $BMRN $ASND https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41633776/biomarins-pipeline-faces-skepticism-as-analyst-questions-future-growth

User Image _Contrairian_ Posted - 10/30/24

$BMRN weekly chart - i think bottom is in -

User Image Thestocktraderhubzee Posted - 10/30/24

$BMRN RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $80 Price Target

User Image david999957 Posted - 10/30/24

$BMRN Took advantage of the algo running stops and bought all the way down to 66. Thank you for the ridiculous plunge.

User Image CallingStorms Posted - 10/30/24

$BMRN please don't hurt me too much

User Image IN0V8 Posted - 10/30/24

$BMRN Opportunity Stifel raises target price to $89 from $87 William Blair cuts to market perform rating

Analyst Ratings
Scotiabank Sector Perform Sep 17, 24
Truist Securities Buy Sep 17, 24
Wells Fargo Overweight Sep 17, 24
RBC Capital Sector Perform Sep 17, 24
B of A Securities Buy Sep 17, 24
Stifel Buy Sep 17, 24
Bernstein Outperform Sep 17, 24
Canaccord Genuity Hold Sep 13, 24
Cantor Fitzgerald Overweight Sep 9, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BIENAIME JEAN JACQUES Director Director Jan 08 Sell 97.29 20,000 1,945,800 425,162 01/11/24
BIENAIME JEAN JACQUES Director Director Jan 08 Option 63.1 20,000 1,262,000 435,162 01/11/24
BIENAIME JEAN JACQUES Director Director Dec 21 Sell 93.99 10,000 939,900 425,112 12/22/23
BIENAIME JEAN JACQUES Director Director Dec 21 Option 63.1 10,000 631,000 435,112 12/22/23
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Dec 13 Sell 95.30 13,764 1,311,709 55,710 12/14/23
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Aug 16 Sell 90 5,000 450,000 60,804 08/17/23
FUCHS HENRY J President, Worldwide.. President, Worldwide R&D Aug 10 Sell 90.4259 12,000 1,085,111 176,187 08/11/23
Guyer Charles Greg EVP, Chief Technical.. EVP, Chief Technical Officer Aug 09 Sell 93.304 5,360 500,109 40,041 08/10/23
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Aug 08 Sell 89.4238 11,000 983,662 69,474 08/09/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Aug 07 Sell 88.2 10,000 882,000 422,732 08/09/23
MEIER RICHARD A Director Director May 12 Option 67.81 8,500 576,385 117,494 05/17/23
HERON ELAINE J Director Director May 12 Option 67.81 8,500 576,385 94,068 05/17/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer May 12 Option 67.81 46,500 3,153,165 472,713 05/16/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer May 11 Sell 94.89 30,000 2,846,700 426,213 05/15/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer May 11 Option 67.81 30,000 2,034,300 456,213 05/15/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 28 Sell 95.12 60,000 5,707,200 426,213 05/11/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 28 Option 67.81 60,000 4,068,600 456,213 05/11/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 06 Sell 96.13 10,000 961,300 425,896 04/10/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 06 Option 67.81 10,000 678,100 435,896 04/10/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Mar 10 Sell 91.37 23,000 2,101,510 487,856 03/14/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Mar 10 Option 67.81 23,000 1,559,630 495,856 03/14/23
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 24 Option 67.81 1,474 99,952 56,725 02/28/23
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Jan 25 Sell 115.9 49,000 5,679,100 41,088 01/27/23
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Jan 25 Option 67.81 49,000 3,322,690 90,088 01/27/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Jan 13 Option 67.81 20,000 1,356,200 330,424 01/18/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Jan 13 Sell 111.9 20,000 2,238,000 320,424 01/18/23
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Jan 13 Sell 114.5 2,500 286,250 27,746 01/17/23
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Jan 13 Option 63.1 2,500 157,750 30,246 01/17/23
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Dec 13 Option 63.1 2,500 157,750 30,246 12/15/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Dec 13 Sell 107.5 2,500 268,750 27,746 12/15/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Dec 02 Option 67.81 5,900 400,079 31,507 12/06/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Dec 02 Sell 104.5 7,001 731,604 27,746 12/06/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Nov 02 Sell 104 1,500 156,000 321,424 12/06/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Nov 23 Option 67.81 3,500 237,335 32,347 11/28/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Nov 23 Sell 98.03 5,379 527,303 28,847 11/28/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Oct 31 Sell 86.55 1,500 129,825 322,824 11/01/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 89.89 4,000 359,560 324,324 10/18/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Aug 12 Sell 94.98 7,000 664,860 328,324 08/16/22
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Aug 11 Sell 95.62 3,000 286,860 44,088 08/12/22
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Aug 09 Option 67.81 47,526 3,222,738 102,777 08/11/22
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Aug 09 Sell 96.14 51,216 4,923,906 55,251 08/11/22
Guyer Charles Greg EVP, Chief Technical.. EVP, Chief Technical Officer Aug 08 Sell 96.56 6,205 599,155 42,168 08/10/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Aug 05 Option 67.81 3,500 237,335 34,226 08/09/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Aug 05 Sell 94.5 3,500 330,750 30,726 08/09/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Jul 08 Sell 89.50 7,337 656,662 30,726 07/12/22
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Jul 08 Sell 90.00 7,398 665,820 58,941 07/11/22
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Apr 29 Sell 78.94 1,308 103,254 54,109 05/31/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 29 Option 37.46 30,000 1,123,800 355,324 05/09/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 29 Sell 82.57 30,000 2,477,100 335,324 05/09/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Apr 29 Option 37.46 11,800 442,028 48,401 05/06/22